Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications

Abstract

Objective:

We aimed to investigate the frequency and clinical significance of antibodies to myelin oligodendrocyte glycoprotein (MOG-abs) in patients who presented with a first episode of seronegative aquaporin 4 antibody (AQP4-ab) longitudinally extensive transverse myelitis (LETM).

Methods:

Epidemiological, clinical, and paraclinical data of 56 patients from three European centres were analysed. Patients were retrospectively tested for MOG-abs and AQP4-abs, by cell-based assays.

Findings:

Thirteen (23.2%) patients were MOG-ab positive. Among the 56 patients, six (10.7%) converted to neuromyelitis optica (NMO), one (1.8%) to multiple sclerosis (MS), nine (16.1%) had recurrent LETM, and 40 (71.4%) remained as monophasic LETM. Compared with seronegative patients, those with MOG-abs were younger (median: 32.5 vs 44 years; p=0.007), had cerebrospinal fluid pleocytosis more frequently (94% vs 45%, p=0.003) and had better outcome (median Expanded Disability Status Scale (EDSS) 2.0 vs 3.0, p=0.027). MOG-ab positive patients also showed an increase risk of optic neuritis relapse and NMO conversion (p=0.010).

Conclusion:

Patients with MOG-abs in AQP4-ab seronegative LETM have clinical distinctive features, higher risk of optic neuritis relapses, and better outcome than patients seronegative.

Keywords

Longitudinally extensive transverse myelitis neuromyelitis optica myelin oligodendrocyte glycoprotein aquaporin-4 antibody multiple sclerosis

Get full access to this article

View all access options for this article.

References

Wingerchuk

Lennon

Pittock

. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–1489.

Trebst

Raab

Voss

. Longitudinal extensive transverse myelitis–it’s not all neuromyelitis optica. Nat Rev Neurol 2011; 7: 688–698.

Weinshenker

Wingerchuk

Vukusic

. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59: 566–569.

Hyun

J-W

Kim

S-H

Huh

S-Y

. Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis. Mult Scler. 2015 May; 21: 710–7.

Kitley

Leite

Küker

. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 2013; 70: 1375–1381.

Chang

K-H

Lyu

R-K

Chen

C-M

. Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies. Mult Scler 2013; 19: 299–307.

Marignier

Bernard-Valnet

Giraudon

. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013; 80: 2194–2200.

Von Büdingen

Tanuma

Villoslada

. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. J Clin Immunol 2001; 21: 155–170.

Reindl

Di Pauli

Rostásy

. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013; 9: 455–461.

10.

Di Pauli

Mader

Rostasy

. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011; 138: 247–254.

11.

Baumann

Sahin

Lechner

. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015; 86: 265–72.

12.

Rostásy

Mader

Hennes

. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013; 19: 1052–1059.

13.

Rostasy

Mader

Schanda

. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012; 69: 752–756.

14.

Kitley

Waters

Woodhall

. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol 2014; 71: 276–283.

15.

Höftberger

Sepulveda

Armangue

. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015; 21: 866–74.

16.

Sato

Callegaro

Lana-Peixoto

. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474–481.

17.

Confavreux

Compston

Hommes

. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 671–676.

18.

Barnes

Benjamin

Bowen

. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59: 499–505.

19.

Kurtzke

. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983;33: 1444–1452.

20.

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

21.

Paty

Oger

Kastrukoff

. MRI in the diagnosis of MS: A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38: 180–185.

22.

Höftberger

Sabater

Marignier

. An optimized immunohistochemistry technique improves NMO-IgG detection: Study comparison with cell-based assays. PLoS One 2013; 8: e79083.

23.

Pröbstel

Dornmair

Bittner

. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011; 77: 580–588.

24.

Ramanathan

Reddel

Henderson

. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflammation 2014; 1: e40.

25.

Saadoun

Waters

Owens

. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2014; 2: 35.

26.

Ikeda

Kiyota

Kuroda

. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler. 2015; 21: 656–9.